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Genotoxicity in vitroThe induction of micronucleated reticulocytes in the bone marrow is a sensitive indicator of chromoso-
mal damage. Therefore, the micronucleus assay in rodents is widely used in genotoxicity and carcino-
genicity testing. A test system based on cultured human primary cells could potentially provide better
prediction compared to animal tests, increasing patient safety while also implementing the 3Rs principle,
i.e. replace, reduce and reﬁne. Hereby, we describe the development of an in vitro micronucleus assay
based on animal-free ex vivo culture of human red blood cells from hematopoietic stem cells. To validate
the method, ﬁve clastogens with direct action, three clastogens requiring metabolic activation, four aneu-
genic and three non-genotoxic compounds have been tested. Also, different metabolic systems have been
applied. Flow cytometry was used for detection and enumeration of micronuclei. Altogether, the results
were in agreement with the published data and indicated that a sensitive and cost effective in vitro assay
to assess genotoxicity with a potential to high-throughput screening has been developed.
 2015 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction doses, providing an improved mechanistical basis for assessingSince 1959, the 3Rs rule, i.e. reduce, reﬁne and replace, is the
foundation of the ethical policy applied to animal testing in
Europe and North America. Due to the vast number of chemicals
and/or their mixtures to be assessed for safety, there is an increas-
ing need to evaluate toxic effects at the cellular level as described
e.g. in the term ‘‘21st century toxicology’’ (Berg et al., 2011). One of
the challenges is to design appropriate tests which rely on a molec-
ular and cellular mechanistic understanding of toxicants mode of
action using in vitro methods based on human cells. Such an
approach allows the evaluation of responses over a wide range ofhuman health risks associated with exposure to genotoxic and/or
carcinogenic compounds. Moreover, it is well known that bioas-
says detecting genotoxicity in animals in some instances have lim-
ited biological relevance for humans as, for example, regarding
different response to toxins in comparison to humans (Krewski
et al., 2011). In vivo assays can also be laborious and
time-consuming, as well as painful to animals.
For genotoxicity assessment, the micronucleus (MN) test in
reticulocytes of bone marrow in rodents is one of the most applied
tests in vivo (http://www.oecd-ilibrary.org). MN originate from
whole chromosomes or parts of chromosomes having been sepa-
rated from the main nucleus, and therefore reﬂect either chromo-
some breakage or impairment of the mitotic spindle. Mature red
blood cells lack DNA and RNA while reticulocytes still contain
RNA. Therefore, these cells with induced MN containing DNA frag-
ment(s) can easily be identiﬁed by ﬂow cytometry (FCM) (Heddle
et al., 2011).
Previously, we have developed a highly sensitive method to
determine the frequency of micronucleated reticulocytes in vivo
in rodents based on dual-laser FCM (Grawe et al., 1992). Using this
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tor of about 10, as compared to manual microscopic scoring
(Abramsson-Zetterberg et al., 1995; Grawe et al., 1998, 1992).
The possibility to automate the evaluation of in vivo MN-test by
FCM has further increased the application of this method in geno-
toxicity testing (Hayashi et al., 2000, 2007). Detailed method pro-
tocols have therefore been published (Dertinger et al., 2003;
Grawe, 2005). For assessing cytogenetic damage, FCM-scoring of
micronucleated erythrocytes in rodents is now a well-established
and efﬁcient platform which is highly predictive towards carcino-
genicity, relatively easy to evaluate and contains improved techni-
cal advantages (Dertinger et al., 2011). The strength of this test is
that it exclusively detects MN arising in the bone marrow and thus
indicates that the genotoxic substance tested is effective in that tis-
sue. Because the hematopoietic cells undergo rapid division, the
test is highly sensitive to genotoxic agents as well as to aneugenic
agents that produce changes in the chromosome number. The
MN-test in newly-formed erythrocytes has also been applied by
us in studies on humans (Abramsson-Zetterberg et al., 2000;
Kotova et al., 2014; Stopper et al., 2005) as well as by others
(Flanagan et al., 2010; Offer et al., 2005).
Based on our previous knowledge and experience in technical
development of the MN-test, we have developed a non-animal
genotoxic test in vitro which is analogous to micronucleus test
in vivo. For this purpose, we have exploited the ex vivo generation
of human erythrocytes from hematopoietic stem cells in conditions
with no animal components as previously described (Giarratana
et al., 2011). First, we showed that it is possible to induce and mon-
itor MN induction by genotoxic agents in ex vivo generated human
reticulocytes. Thereafter, in order to validate the method, a panel of
clastogenic agents with direct action (c-radiation, mitomycin C,
methyl methansulfonate, etoposide, dibenzo(a,l)pyrene-11,12-di
hydrodiol-13,14-epoxideand), clastogens requiring metabolic acti-
vation (7,12-dimethylbenz(a)antracene, benzo(a)pyrene,
cyclophosphamide monohydrate, dibenzo(a,l)pyrene-11,12-dihy
drodiol) as well as aneugens (colcemid, griseofulvin, vincristine
sulfate, bisphenol A) and non-genotoxic compounds (benzyl alco-
hol, ethylenediaminetetraacetic acid, sodium chloride) has been
tested. For metabolic activation, rat S9 mix and human S9 mix as
well as co-culture with HepaRG and XEM2 cell lines have been
applied.2. Materials and methods
2.1. Cells and culture conditions
2.1.1. Cultured red blood cells (RBCs)
The culture conditions described here allow highly selective dif-
ferentiation of CD34+ hematopoietic stem cells into fully matured
RBCs. CD34+ cells have been isolated either from cord blood (CB)
cells or leukapheresis (LK) from healthy individuals once informed
consent obtained.
CD34+ cells were isolated by supermagnetic microbead selec-
tion by the use of Mini-MACS columns (Miltenyi Biotec; 94% ± 3%
purity). The cells were cultured in the presence of Iscove
Modiﬁed Dulbecco’s Medium (IMDM) supplemented with stabi-
lized glutamine (Biochrom) containing 330 lg/mL human
holo-transferrin (Scipac), 10 lg/mL recombinant human insulin
(Incelligent SG; CellGen), 2 IU/mL heparin (Choay), 5% sol-
vent/detergent virus-inactivated human plasma (Etablissement
Français du Sang) and with sequential addition of 100 ng/mL stem
cell factor (SCF; PeproTech), 5 ng/mL interleukin-3 (IL-3;
PeproTech) and 3 IU/mL erythropoietin (Epo; Eprex). On day 4,
one volume of cell culture was diluted in four volumes of fresh
medium containing SCF, IL-3 and Epo. On day 8, the cells wereresuspended at 105 cells/mL in fresh medium supplemented with
SCF and Epo. In the second phase (day 11–day 18), the cells were
adjusted to 1  106 cells/mL and cultured in fresh medium supple-
mented with Epo alone. By day 15, the mean cell ampliﬁcation of
CD34+ cells reached a plateau of approximately 30000-fold for
LK and 100000-fold for CB cells.
2.1.2. Metabolic activation
For metabolic activation, one part of rat S9 liver postmitochon-
drial fraction (S9) (MOLTOX, Trinova Biochem, Germany) and 1.5
parts cofactor mixture were used. The cofactor mixture was
ß-nicotinamid adenine dinucleotide phosphate sodium salt and
glucose-6-phosphate sodium salt dissolved in IMDM (ﬁnal concen-
tration in cell culture was 0.6 mmol/L and 3.75 mmol/L respec-
tively). As an alternative, human S9 (XenoTech, USA) with the
same cofactor mixture as for rat S9 was applied. XEM2 cells were
grown in Dulbeccos modiﬁed Eagle’s media (DMEM) containing
9% serum and 0.9% penicillin/streptomycin, in 37 C at 5% CO2.
The medium for HepaRG cells (Biopredic International, France)
was prepared according to user guide from a supplier. For
co-culture with HepaRG or XEM2 cells in inserts, HTS
Transwell-24 well plates with 0.4 lm polycarbonate membrane
were used (Corning Incorporated, USA).
2.2. Compounds and c-radiation source
The compounds used were paraformaldehyde (Sigma–Aldrich,
Germany, CAS no 30525-89-4), May-Grünwald solution (Merck,
Germany), Giemsa solution (Merck, Germany),
phosphate-buffered saline (PBS; Sigma–Aldrich, Germany),
glucose-6-phosphate sodium salt (Sigma–Aldrich, Germany, CAS
no 54010-71-8), ß-nicotinamid adenine dinucleotide phosphate
sodium salt (Sigma–Aldrich. Germany, CAS no 698999-85-8),
GlutaMax (LifeTechnologies, USA), Iscove’s Modiﬁed Dulbecco’s
Medium (IMDM, Sigma–Aldrich, Germany), dimethylsulfoxide
(DMSO, Scharlau, CAS no 67-68-5), Hoechst 33342 (Sigma–
Aldrich, Germany, CAS no 23491-52-3), Thiazole orange (Sigma–
Aldrich, Germany, CAS no 107091-89-4). Compounds tested are
listed in Table 1. The ﬁnal concentration of DMSO or water in com-
plete medium did not exceed 0.1% (v/v). In all cases of c-radiation,
the cells were irradiated with a single acute dose by 137Cs source at
the dose-rate of 0.37 Gy/min.
2.3. Treatment schedule
2.3.1. Compounds with direct action
During the initial experiments, the cells were treated on days
11–15 in order to test different culture conditions. The cells were
transferred from T-ﬂasks into 24-wells plates in concentration
1  106 cells per mL per well in a ﬁnal volume of 1 mL per well.
For testing in 96-wells plates, a ﬁnal volume was 0.2 mL per well.
To test a short-term or prolonged treatment to genotoxic agents
with a direct mechanism of action, i.e. without metabolic activa-
tion, cells were treated for 1 h or 24 h and had a recovery time of
24-, 48-, 72- or 120 h. After the treatment, the cells were washed
twice, ﬁrst time with 9 ml and then with 7 ml PBS.
2.3.2. Compounds that require metabolic activation
For testing of genotoxic agents which require metabolic activa-
tion, cells were treated with a respective chemical for 3 h
(short-term exposure) or 24 h (prolonged treatment) with ﬁnal
concentration of 1% or 2% microsomal liver cell fraction from rat
(S9 mix) followed by 69- or 48-h recovery time, respectively. For
tests with human S9 mix, cells were treated with a respective
chemical for 3 h with ﬁnal concentration of 1%, 2%, 5% or 10%
mix followed by 69-h recovery time. XEM2 and HepaRG cells were
Table 1
Tested compounds.
Category Chemical CAS
No.
Supplier
1. Clastogens active without metabolic activation
Mitomycin C 50-07-
7
Sigma–Aldrich
Methyl methansulfonate 66-27-
3
Fluka
Etoposide 33419-
42-0
Sigma–Aldrich
Dibenzo(a,l)pyrene-11,12-
dihydrodiol-13,14-epoxide
The Biochemical
Institute for
Environmental
Carcinogens
2. Clastogens requiring metabolic activation
Benzo(a)pyrene 50-32-
8
Sigma–Aldrich
Cyclophosphamide
monohydrate
6055-
19-2
Sigma–Aldrich
Dibenzo(a,l)pyrene-11,12-
dihydrodiol
The Biochemical
Institute for
Environmental
Carcinogens
7,12-
Dimethylbenz(a)antracene
57-97-
6
Sigma–Aldrich
3. Aneugens
Bisphenol A 80-05-
07
Sigma–Aldrich
Colcemid 477-
30-5
Gibco
Griseofulvin 126-
07-8
Sigma–Aldrich
Vincristine sulfate 2068-
78-2
Sigma–Aldrich
4. Negative substances
Benzyl alcohol 100-
51-6
Sigma–Aldrich
Ethylenediaminetetraacetic
acid
6381-
92-6
Scharlau
Sodium chloride 7647-
14-5
Merck
N. Kotova et al. / Toxicology in Vitro 29 (2015) 1897–1905 1899used for co-cultivation in inserts or directly in wells. All types of
co-culture were applied just before the treatment and directly
afterwards the cells were washed by PBS twice as described above.
2.4. Cell harvesting and ﬁxation
After the treatment, the cells were harvested by collection into
15 ml FALCON-type tubes, and washed twice in 7 ml PBS. The
tubes were centrifuged at 275 ⁄ g for 8 min at room temperature.
Afterwards, pellets were re-suspended in 1 mL of fresh medium
pre-warmed to 37 C and transferred to new 24-wells plate for
recovery incubation. After the recovery time, the cells were again
collected into 15 mL tubes and washed twice as described above.
The pellets were re-suspended and the cells were ﬁxed by addition
of 4 ml 2% paraformaldehyde in PBS (warmed at max 80 C and
cooled down to room temperature), added drop wise. Thereafter
the cells were transferred to 5 ml polystyrene round-bottom
FALCON-type tubes (12  75 mm) which were tightly capped and
stored in the dark at room temperature for at least 3 days.
Thereafter, the ﬁxed cells were transferred to +4 C for further stor-
age up to 3 months until FCM analysis.
2.5. Flow cytometry based MN detection
2.5.1. Staining of cells
The cells were stained according to Abramsson-Zetterberg et al.
(2000). In brief, the coded FCM-tubes with the ﬁxed cells were cen-
trifuged at 400 ⁄ g for 5 min at room temperature. The pellets wereresuspended in 0.5 mL staining solution prepared by mixing 10 mL
PBS with 7.5 lL Hoechst 33342 (500 lM in puriﬁed water) for
DNA-staining and 2 lL Thiazole orange (1 mg/mL in methanol)
for RNA-staining. The tubes were incubated at 37 C for 60 min
and kept at +4 C until FCM analysis the same day.
2.5.2. FCM analysis
The coded stained samples were analyzed by FCM at a rate of
1000–2500 cells per second with a threshold in forward scatter
(FSC) set to include all intact cells. FACSVantage SE or LSRII ﬂow
cytometers (BD Biosciences, CA, USA), both equipped with UV exci-
tation capability and available at SciLifeLab BioVis platform at
Uppsala University in Sweden, were used. Using BD FACSDiva soft-
ware (BD Biosciences, CA, USA) peak values for FSC, SSC, Thiazole
orange ﬂuorescence and Hoechst 33342 ﬂuorescence signals were
collected. The FSC signals were acquired using a linear scale and
the SSC, Thiazole orange and Hoechst 33342 signals were acquired
using a log scale. From each sample, two separate FCM-analyses
were done, generally at least of 200000 events each were collected
resulting in about 400000–800000 cells analyzed per treatment.
FCM analysis was applied to obtain all data on MN measurements
presented in this paper.
2.6. Morphology and viability
For microscopic analyses, samples were taken when harvesting
the cells. The sampled cells were diluted with PBS and spun onto
slides by cytocentrifugation (Shandon Cytospin 2, 700 rpm for
3 min). The next day, cells were ﬁrst stained with May-Grünwald
for 3 min, rinsed in tap water for 1 min and thereafter stained with
Giemsa (1:10 in tap water) for 15 min. The slides were thereafter
washed, dried and mounted. The percentage of enucleated reticu-
locytes in total cells on stained slides was counted as enucleation
rate. Viable cell counting was based on trypan blue exclusion and
conducted by microscope scoring.
2.7. Statistical analysis and positivity criteria for MN test
Regression analysis was performed in order to test for a trend in
the increase of micronucleated cells across the treatment range
(dose-related). A compound was considered positive if it induced
the frequency of MN (fMN) according to the following criteria:
(a) the induced fMNwas above the maximum value of the negative
control; (b) the fMN showed at least twofold increase; and (c) the
data analysis was statistically signiﬁcant, i.e. p < 0.05 (regression
analysis).3. Results
3.1. Cultivation of RBCs in 24-well plates can be utilized for
genotoxicity testing in terms of MN-induction
The present protocol allows ex vivo erythroid differentiation
under animal-free culture conditions and was optimized for mas-
sive expansion and terminal differentiation of erythroblasts start-
ing from human hematopoietic stem cells isolated from bone
marrow or cord blood (Giarratana et al., 2011). Following this pro-
tocol, we have enhanced the method to cultivate erythroblasts in
24-well plates for genotoxicity testing in terms of MN-induction.
The cultured human CD34+ cells followed a two-phase
large-scale ampliﬁcation toward erythrocytes production, i.e.
expansion (day 0–day 10) and differentiation (day 11–day 18)
(Fig. 1). The immunophenotypic characterization of erythroid com-
mitment and maturation in terms of expression of the relevant ery-
throid markers CD71, CD36 and CD235a was previously reported
Fig. 1. Representative pictures of cells undergoing erythroid differentiation on days 7, 10, 12, 15 and 18 of culture after May-Gründwald-Giemsa staining. Enucleation rates
are respectively 0%, 1%, 5%, 53% and 82% (magniﬁcation 60).
Fig. 2. Induction of MN in human erythroblasts detected by ﬂow cytometry after 1 h treatment with MMC on different days of terminal differentiation (TD) followed by cell
harvest on day 12 up to day 19 of cell culture. The enucleation rate at day 11 was up to 5%, day 12 – about 20%, day 15 – up to 80%.
Fig. 3. Induction of MN in human erythroblasts detected by ﬂow cytometry after 1 h treatment with Mitomycin C and acute c-radiation. The cells were recovered for 24-, 48-
and 72-h after exposure. ⁄⁄⁄P-value < 0.001, ⁄⁄P-value < 0.01, N.S. = not signiﬁcant.
1900 N. Kotova et al. / Toxicology in Vitro 29 (2015) 1897–1905(Giarratana et al., 2011). Furthermore, we have studied the optimal
time frame for treatment, which is crucial since the exposure to
genotoxic agents must be conducted at the beginning ofdifferentiation in order to be able to study the endpoint. As a result,
it was concluded that the most optimal time point to conduct the
treatment is immediately after switching to differentiation phase,
N. Kotova et al. / Toxicology in Vitro 29 (2015) 1897–1905 1901i.e. at day 11, to get the optimal MN induction (Fig. 2). Since the
recovery time might be crucial while studying genotoxic response,
different time schedules were tested. As a result, 48- or 72-h recov-
ery time was found to be the most optimal in order to detect geno-
toxic response in terms of induced fMN (Figs. 2 and 3). Therefore,
harvesting of cells only 48- or 72-h after the initiated treatment
was applied afterwards. At time of harvesting, a slight difference
in the enucleation rate of CB (59% ± 12%) and LK (42% ± 16%) was
found. This is related to the source of cells as usually observed in
our previous experiments (Giarratana et al., 2005).Table 2
MN induction after 24 h treatment with direct acting clastogens.
Cell
culture
Treatment %Viabilitya %ERb %MNc Foldd Statistical
signiﬁcance
Mitomycin C (lg/mL)
LK 0 92.1 31 2.9 1.0 ***
0.025 92.1 31 5.5 1.9
0.050 90.1 21 7.9 2.7
0.10 88.2 34 10.4 3.6
CB 0 99.1 63 2.8 1.0 **
0.025 100 52 13.4 4.8
0.050 99.5 60 19.9 7.2
0.10 96.8 49 23.0 8.3
Methyl methanesulfonate (lg/mL)
LK 0 93.7 23 2.4 1.0 **
1.3 93.1 28 3.5 1.5
2.6 91.3 27 3.4 1.4
5.0 92.7 ND 5.9 2.5
CB 0 95.1 67 2.6 1.0 ***
1.3 95.4 73 3.0 1.2
5.1 96.0 56 8.5 3.3
13 92.3 40 13.0 5.0
Dibenzo[a,l]pyrene-11,12-dihydrodiol-13,14-epoxide (nM)
LK 0 ND ND 1.5 1.0 ***
1 ND ND 4.0 2.7
3 ND ND 6.5 4.5
5 ND ND 7.7 5.3
Etoposide (lg/mL)
LK 0 ND ND 1.5 1.0 ***
0.05 ND ND 3.7 2.5
0.10 ND ND 5.4 3.7
0.15 ND ND 8.3 5.7
0.20 ND ND 12.4 8.5
0.30 ND ND 14.5 9.9
CB 0 96.1 67 2.1 1.0 ***
0.05 97.9 67 5.7 2.7
0.15 96.7 62 13.2 6.2
0.30 94.3 72 20.7 9.7
Gamma irradiation (Gy)
LK 0 94.4 45 3.1 1.0 ***
0.1 92.2 24 3.8 1.3
0.5 91.5 46 11.7 3.8
CB 0 96.3 66 2.5 1.0 ***
0.1 94.0 63 2.4 1.0
0.25 93.2 64 7.8 3.2
0.5 96.0 65 12.4 5.0
LK – human red blood cells from leukapheresis.
CB – human red blood cells from cord blood.
ND – not determined.
a Viability based on trypan blue exclusion.
b Enucleation rate (ER) = % of enucleated reticulocytes in total cells.
c %MN = % micronucleated erythrocytes.
d Fold = %MN of the treated cultures/%MN of the negative control cultures.
** P-value < 0.01.
*** P-value < 0.001.3.2. Directly acting genotoxic agents induced MN levels
To test chemicals with different mechanisms of action such as
known clastogens and aneugens, the cells were treated in
24-well plates for 24 h with 48-h recovery time.
3.2.1. Clastogenic agents
The validation set of agents included c-radiation, etoposide,
methyl methanesulfonate (MMS), mitomycin C and dibenzo(a,l)pyr
ene-11,12-dihydrodiol-13,14-epoxide (DBPDE) (Table 2).
According to criteria, positive response in terms of increased fMN
was observed for all treatments. Typical FCM-plots for respective
treated and untreated cells stained with Hoechst 33342 and
Thiazole Orange are presented in Fig. 4A. Representative images
of MN in erythrocytes treated with c-irradiation (0.5 Gy) and
MMC (0.1 lg/ml) are shown in Fig. 4B.
3.2.2. Aneugenic agents
The validation set of agents included bisphenol A, colcemid,
griseofulvin and vincristine sulfate (Table 3). Colcemid and vin-
cristine sulfate induced positive response in terms of MN induc-
tion. A threshold in MN induction was observed for these agents.
Treatment with bisphenol A and griseofulvin showed no MN
induction in the present test system.
3.2.3. Negative compounds
The validation set of known non-genotoxic agents included
benzyl alcohol, ethylenediaminetetraacetic acid (EDTA) and
sodium chloride (NaCl) (Table 4). According to the chosen positiv-
ity criteria for MN induction, none of the negative compounds
resulted in positive responce.
To further improve high-throughput feature of the test, the
treatments with MMC, MMS, colcemide and c-irradiation were
conducted in 96-well plates giving responses comparable to
24-well plate cultures in terms of MN induction (data not shown).
3.3. Induction of MN was achieved after treatments with genotoxic
agents requiring metabolic activation
Since there are no well-known aneugenic agents requiring
metabolic activation, only agents with clastogenic action were
tested.
The 24-h treatment with rat S9 resulted in high toxicity which
was in agreement with the published data (Ku et al., 2007), and
was therefore excluded for further testing. Further, compared to
1% rat S9 mix, 2% rat S9 mix resulted in a decrease in enucleation
rate (data not shown) and therefore was not applied for further
investigation. Since the recommended short-time exposure with
S9 mix is limited to 2–4 h (Ku et al., 2007), the cells were treated
with a respective chemical with 1% rat S9 mix for 3 h followed
by 69-h recovery time. The initial validation set of agents included
3-h treatment with cyclophosphamide (CP), benzo(a)pyrene
(B(a)P) and dimethylbenz(a)antracene (DMBA) metabolized by
1% rat S9 (Table 5). The obtained results from all three compounds
indicated a signiﬁcant induction of fMN.
The ﬁrst tested metabolizing system not containing any animal
components was human S9 mix at 1%, 2%, 5% or 10% concentration.
As for the experiments using rat S9 mix, the cells were treated with
a respective chemical with human S9 mix for 3 h followed by 69-h
recovery time. None of the applied human S9 mix concentrations
introduced an adverse effect in enucleation rate which stably ran-
ged between approximately 50% and 60%. B(a)P and CP (2, 4,
6 lg/mL and 1, 2.5, 5 lg/mL respectively) were tested in different
series of experiments, but none of them showed an induction in
fMN (data not shown).
Fig. 4A. Representative plots of ﬂow cytometric data for: (a and e) negative control; (b–d) cell culture treated with c-radiation; (f–h) cell culture treated with MMC. Gate P2
represents population of erythrocytes, P3 – micronucleated erythrocytes, P4 – nucleated erythroblasts.
Fig. 4B. Pictures of representative slides showing micronucleated human reticulocytes after treatment with (a) 0.5 Gy c-radiation and (b) 0.1 lg/mL MMC (magniﬁcation
100).
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ment followed by 48-h recovery was applied. XEM2 cells were
used to evaluate the metabolic activation through co-cultivation
in inserts or directly in wells. It was clear that co-cultivation in
inserts did not provide metabolic activation (data not shown)
and therefore only co-cultivation directly in wells was thereafter
conducted for XEM2 and HepaRG cells. Signiﬁcant inductions of
MN by DMBAwith HepaRG co-culture as well as by dibenzo[a,l]pyr
ene-11,12-dihydrodiol (DBPD) with XEM2 and HepaRG co-culture
were obtained (Table 6). B(a)P induced fMN almost 2-fold with
HepaRG co-culture, however the trend was not signiﬁcant
(Table 6). CP showed no induction of fMN with neither HepaRG
nor XEM2 co-culture.
Except for vincristine sulfate treatments (Table 3), no differ-
ences in terms of positive MN induction was observed between
cultured RBCs generated from LK or CB cells. This exception
remains unclear and needs further investigation. Cell viability after
recovery time was generally >85%. The viable cell yields were
mostly found to be lower for treated cells vs. control cells (data
not shown). Cell proliferation rate and cell death were not explic-
itly measured, thus reductions in viable cell yields cannot be
speciﬁcally attributed to cytotoxicity or cytotoxic mechanisms.
However, we believe that decreased enucleation rate is an indica-
tor of cytotoxic exposure in this erythropoetic culture system.4. Conclusions
According to the developed protocol, the most appropriate time
point to conduct the treatment with genotoxic agents is on day 11
of cell culture in order to study the endpoint. This obtained time
point is in agreement with previously described timetable of ery-
thropoiesis in vivo in humans (Grawe et al., 2005). It was also
observed that day 15 of cell culture is the most appropriate for har-
vesting of cells to detect the induced fMN. As a result of high
expansion rate and complete differentiation process of cultured
RBCs, the samples can easily be analyzed within a rather short
time.
The conducted experiments have proved that RBCs culture was
stable under the presence of tested chemicals for both short-term
exposure (1 h or 3 h) and prolonged treatment (24 h). In this study
we showed that genotoxicity testing of both clastogenic and aneu-
genic compounds by this method are in agreement with published
data. It was indicated that this method has the potential to be sen-
sitive enough for induction of MN by 0.025 lg/mL MMC treatment
(Table 2). This is comparable to the lowest dose applied in other
studies with MN-test in vitro (Hashimoto et al., 2010; Sobol
et al., 2012). Moreover, the dose response was detectible down to
0.25 Gy of c-radiation (Table 2). Interestingly, an approximately
sixfold of MN induction by 1.0 Gy c-radiation (Fig. 3) is in
Table 3
MN induction after 24 h treatment with aneugens.
Cell
culture
Treatment %Viabilitya %ERb %MNc Foldd Statistical
signiﬁcance
Vincristine sulfate (lg/mL)
LK 0 ND ND 1.5 1.0 NS
0.025 ND ND 4.3 2.9
0.050 ND ND 4.5 3.1
0.075 ND ND 3.4 2.3
0.100 ND ND 4.3 2.9
CB 0 94.6 78 2.4 1.0 ***
0.003 94.4 43 5.3 2.2
0.005 93.2 54 5.3 2.2
0.007 91.6 54 6.6 2.7
0.0125 91.6 39 7.2 3.0
0.0250 92.4 33 7.1 2.9
Bisphenol A (lg/mL)
LK 0 ND ND 1.5 1.0 NS
20 ND ND 0.8 0.6
30 ND ND 1.5 1.0
40 ND ND 1.5 1.0
CB 0 96.0 63 2.6 1.0 NS
5 97.0 63 2.0 0.8
10 96.4 69 1.5 0.6
20 95.0 67 1.3 0.5
40 90.0 47 1.7 0.7
Griseofulvin (lg/mL)
LK 0 ND ND 1.5 1.0 NS
4 ND ND 1.4 1.0
7 ND ND 1.5 1.0
14 ND ND 1.1 0.8
21 ND ND 1.2 0.8
CB 0 94.8 63 2.0 1.0 NS
20 91.6 70 1.4 0.7
36 94.4 59 1.2 0.6
Colcemid (lg/mL)
CB 0 95.8 72 3.2 1.0 ***
0.01 96.0 65 2.6 0.8
0.02 94.8 69 5.1 1.6
0.04 91.8 61 6.9 2.2
0.06 90.4 64 7.6 2.4
0.08 89.2 57 7.8 2.4
LK – human red blood cells from leukapheresis.
CB – human red blood cells from cord blood.
NS – not signiﬁcant; ND – not determined.
a–d See footnotes of Table 2.
*** P-value < 0.001.
Table 4
MN induction after 24 h treatment with negative and false positive compounds in
cord blood cells culture.
Treatment %Viabilitya %ERb %MNc Foldd Statistical signiﬁcance
Benzyl alcohol (lM)
0 96.0 73 2.2 1.0 NS
10 94.4 71 2.2 1.0
100 98.0 67 2.2 1.0
1000 96.5 69 2.0 0.9
4825 97.8 79 1.8 0.8
Sodium chloride (lg/mL)
0 95.6 64 2.7 1.0 ***
500 97.1 71 2.9 1.1
1000 93.7 64 3.2 1.2
2000 94.1 65 3.6 1.3
Ethylenediaminetetraacetic acid (lg/mL)
0 96.0 64 2.7 1.0 NS
500 95.8 79 1.8 0.7
1000 88.5 52 1.3 0.5
2000 87.3 49 2.2 0.8
NS – not signiﬁcant.
a–d See footnotes of Table 2.
*** P-value < 0.001.
Table 5
MN induction with clastogens requiring metabolic activation (1% rat S9 mix) after 3 h
treatment followed by 69 h recovery.
Cell
culture
Treatment %Viabilitya %ERb %MNc Foldd Statistical
signiﬁcance
Benzo(a)pyrene (lg/mL)
CB 0 97.2 ND 2.6 1.0 *
1.0 94.8 66 3.5 1.4
2.0 94.4 80 6.3 2.5
4.0 92.4 49 6.4 2.5
Cyclophosphamide (lg/mL)
LK 0 94.8 54 2.9 1.0 ***
0.1 91.6 60 3.6 1.2
0.3 90.8 69 4.7 1.6
1.0 90.8 70 11.3 3.9
2.5 91.2 51 22.4 7.8
CB 0 96.4 64 2.2 1.0 ***
0.3 94.6 57 2.7 1.3
2.5 95.9 62 17.3 8.0
5.0 96.0 36 23.8 10.9
7,12-Dimethylbenz(a)antracene (lg/mL)
LK 0 94.8 54 2.9 1.0 *
0.5 93.6 43 5.6 1.9
1.0 94.0 ND 6.9 2.4
CB 0 96.7 61 2.2 1.0 ***
0.5 95.6 ND 3.6 1.6
1.0 96.4 35 4.8 2.1
1.5 92.2 53 5.1 2.3
2.0 92.4 21 5.5 2.5
LK – human red blood cells from leukapheresis.
CB – human red blood cells from cord blood.
ND – not determined.
a–d See footnotes of Table 2.
* P-value < 0.05.
*** P-value < 0.001.
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model of erythropoiesis. Concerning aneugenic agents, colcemid
and vincristine sulfate induced positive response in terms of MN
induction containing a threshold (Table 3) which is in agreement
with data reported for MN test in vivo (Cammerer et al., 2010).
Although, bisphenol A and griseofulvin have previously been
shown to give a positive effect in other types of MN test in vitro
(Hashimoto et al., 2010; Johnson and Parry, 2008), no effect in
terms of MN induction have been reported here, which is in agree-
ment with ﬁndings using MN test in vivo (Labay et al., 2001;
NTP/NIH/USA).
While treated to aneugenic agents, the viability of cultured
RBCs was rather stable. However, FCM plots indicated that the
treated cells may undergo defragmentation which can result in
decreased enucleation rate. The presented assay allows size dis-
crimination of smaller MN induced by clastogens from larger ones
induced by aneugens, a feature that has previously been applied by
others (Matsuoka et al., 1999; Torous et al., 1998). Application of
ﬂow sorting is another advantage of the method allowing enrich-
ment of only MN-cells. It would therefore allow possibility to studymechanisms of MN induction by FISH-analysis or similar tech-
niques as being previously described (Grawe et al., 1997).
As a reference to the tests of animal-free metabolizing systems,
the commonly used rat S9 mix was applied (Table 5). Also, a
co-culture with XEM2 cell line, previously genetically engineered
derivative of the V79 Chinese hamster lung ﬁbroblasts to stably
express active cytochrome CYP1A1 (Ellard et al., 1991) was used
to evaluate the metabolic activation through co-cultivation in
Table 6
MN induction with clastogens requiring metabolic activation (co-cultivation directly in wells) after 24 h treatment followed by 48 h recovery in cord blood cell culture.
Treatment XEM2 HepaRG
%ERb %MNc Foldd Statistical signiﬁcance %ERb %MNc Foldd Statistical signiﬁcance
7,12-Dimethylbenz(a)antracene (lg/mL)
0 57 2.0 1.0 NS 68 2.1 1.0 ***
0.5 ND ND ND 69 4.3 2.1
1.0 ND ND ND 69 4.1 1.9
1.5 60 3.7 1.8 64 4.3 2.0
2.0 ND ND ND 63 3.7 1.8
Cyclophosphamide (lg/mL)
0 54 1.9 1.0 NS 68 2.1 1.0 NS
2.5 57 1.5 0.8 69 1.8 0.9
5.0 45 1.5 0.8 ND ND ND
Benzo(a)pyrene (lg/mL)
0 ND ND ND 77 1.8 1.0 NS
2.0 ND ND ND 81 2.9 1.6
4.0 ND ND ND 62 3.4 1.9
Dibenzo[a,l]pyrene-11,12-dihydrodiol (nM)
0 55 1.9 1.0 *** 65 2.2 1.0 ***
1.5 62 3.6 1.9 63 4.6 2.0
3.3 53 4.4 2.2 62 3.1 1.4
5.0 59 6.9 3.5 61 5.6 2.5
10 60 8.1 4.2 63 8.3 3.7
15 49 8.2 4.2 ND ND ND
25 ND 8.4 4.3 ND ND ND
NS – not signiﬁcant; ND – not determined.
b–d See footnotes of Table 2.
*** P-value < 0.001.
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provide metabolic activation, only co-cultivation directly in wells
was thereafter conducted. As previously proposed candidates,
two animal-free metabolizing systems, human S9 mix (Kirkland
et al., 2007; Ku et al., 2007) and HepaRG cell line (Lubberstedt
et al., 2011), were applied. Our results preliminary indicate that
there is no common animal-free metabolic system which has
potential efﬁciency similar to rat S9 applicable to RBCs cultures
(Tables 5 and 6). Therefore, for the present method to be used for
alternative genotoxic testing of a wide range of agents, metabolic
activation by rat S9 mix is required. However, we believe that an
efﬁcient animal-free metabolic system would also work as soon
as such a system is available.
The present method provides a robust in vitro tool to assess the
potential risk of chemicals completely avoiding animal compo-
nents and/or decreasing animal testing. It has high sensitivity par-
ticularly due to implementation of unmodiﬁed primary human
stem cells but also due to high speed analysis (up to 300 000 cells
in approximately 2 min) and potential robot application towards
high throughput application. Moreover, the source of CB cells is
unlimited and easily available. As a putative extrapolation of the
data reported, an average cord blood sample of approximately
50 ml could generate enough cells to screen up to 30000 different
genotoxic compounds which is far more compared to the current
test in rodents. In addition to the potential to be used as a genotox-
icity screening assay, the present in vitro test has a high relevance
to human health assessment. This is due to the fact that the
methodology of RBCs culture is adaptable to CD34+ cells of diverse
origins such as peripheral blood, bone marrow or cord blood, i.e.
any source of hematopoietic stem cells of an individual. It opens
a potential for clinical applications and might be used in individu-
alized medicine to predict genotoxic outcome induced by certain
medical treatments, i.e. cytostatics or radiotherapy.
In conclusion, an alternative in vitro test for detection of geno-
toxic damage entirely based on human stem cells according to
3Rs principle is hereby described. By using this method, human
erythroblasts differentiated in vitro into mature erythrocytesexhibit the same stages as deﬁned in vivo. The method allows a
cost-effective production of high relevance data and the capture
of genotoxic damage induced at very early stages of development.
The obtained results indicate that this developed in vitro genotoxic
test is relevant, sensitive, highly reproducible, easy to perform and
evaluate, enables high-throughput application, and last but not
least has the potential to reduce animal testing while retaining,
or even improving, the quality and applicability of generated data.
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